Efficacy News and Research

RSS

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.

28 Aug 2014

Cancer patients require better treatment for depression

Findings from three research studies have shown that around three quarters of cancer patients who suffer from major depression do not receive treatment for their depression and that a newly developed medical programme has proven more effective than standard care at reducing depression in these patients.

28 Aug 2014

Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide.

28 Aug 2014

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology.

28 Aug 2014

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.

27 Aug 2014

TxCell announces five new patents for core technology and ASTrIA platform

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, today announces that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014.

27 Aug 2014

Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer.

27 Aug 2014

Scientists find that DNA repair drug could help treat leukaemia, other cancers

A team of scientists led by Research Associate Professor Motomi Osato and Professor Yoshiaki Ito from the Cancer Science Institute of Singapore at the National University of Singapore found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukaemia and other cancers.

26 Aug 2014

Auriculotherapy may help in managing chronic constipation

Nearly 1 in 6 adults worldwide may suffer from chronic constipation and, over time, the disorder can cause serious complications. Auriculotherapy, a form of acupuncture that involves stimulating targeted points on the outer ear, may help in managing constipation.

26 Aug 2014

Ruthigen gets DMC recommendation to begin RUT58-60 Phase 1/2 clinical trial

Ruthigen Inc., a biopharmaceutical company focused on improving patient outcomes and reducing healthcare costs in invasive procedures, has announced that its lead drug candidate, RUT58-60, has received a recommendation from the Data Monitoring Committee to begin enrolling patients in the Company's planned Phase 1/2 clinical trial.

26 Aug 2014

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody.

25 Aug 2014

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform.

25 Aug 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting.

25 Aug 2014

Clinical study shows long-term effectiveness of Orthocell’s Ortho-ATI™ for treatment resistant tennis elbow

Regenerative medicine company Orthocell Limited has today released results from a long-term clinical study into its Ortho-ATI™ treatment for tennis elbow that provides evidence of the durability and long term success of this treatment.

25 Aug 2014

Novel "man and machine" decision support system for diagnosing malaria infection

A Finnish-Swedish research group at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, and Karolinska institutet, Stockholm, has developed a novel "man and machine" decision support system for diagnosing malaria infection.

22 Aug 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

Investigational drug focuses on slowing Alzheimer's disease progression

Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug that proposes to do just that.

21 Aug 2014

Regular blood transfusion therapy reduces recurrence of strokes in kids with sickle cell anemia

Vanderbilt-led research, as part of an international, multicenter trial, found regular blood transfusion therapy significantly reduces the recurrence of silent strokes and strokes in children with sickle cell anemia who have had pre-existing silent strokes, according to study results released today in the New England Journal of Medicine (NEJM).

21 Aug 2014

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm.

21 Aug 2014